Drug
Repotrectinib
Repotrectinib: highest development phase Phase 3, developed by Bristol-Myers Squibb, United Therapeutics. 2 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Bristol-Myers Squibb, United Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| Repotrectinib NCT06140836 | Phase 3 | Carcinoma, Non-Small-Cell Lung |
| Oral repotrectinib (TPX-0005) NCT03093116 | Phase 1/2 | Locally Advanced Solid Tumors |
Latest
No recent events.
Follow Repotrectinib on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.